Parasite-induced Lipoxin A₄ Is an Endogenous Regulator of IL-12 Production and Immunopathology in Toxoplasma gondii Infection

Julio Aliberti,¹ Charles Serhan,² and Alan Sher¹

¹Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892
²Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Research, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115

Abstract

The production of interleukin (IL–12) is critical for the development of interferon (IFN)-γ-dependent resistance to Toxoplasma gondii. Nevertheless, when this response is dysregulated, such as occurs in the absence of IL–10, the uncontrolled inflammation that results can have lethal consequences for the host. Recently, we demonstrated that lipoxin (LX)A₄, an eicosanoid mediator that depends on 5-lipoxygenase (LO) for its biosynthesis, exerts a regulatory role on dendritic cell IL–12 production triggered artificially by a T. gondii extract. We now formally establish the physiological relevance of this pathway in the systemic control of IL–12 production induced by live T. gondii infection and demonstrate its function to be distinct from that of IL–10. Thus, T. gondii–exposed wild-type, but not 5-LO–deficient animals, produced high levels of serum LXA₄ beginning at the onset of chronic infection. Moreover, 5-LO⁻/⁻, in contrast to wild-type mice, succumbed during the same period displaying a marked encephalitis. The increased mortality of the 5-LO⁻/⁻ animals was also associated with significant elevations of IL-12 and IFN-γ and was completely prevented by the administration of a stable LXA₄ analogue. Together, these findings demonstrate a new pathway involving the induction of host LXs for the in vivo regulation of proinflammatory responses during microbial infection.

Key words: Toxoplasma gondii • interleukin-12 • eicosanoid • lipoxygenase • lipoxin A₄

Introduction

Cell-mediated immune responses to infectious agents must be carefully regulated to avoid damage to host tissues. Cytokines, such as IL-12, IFN-γ, and TNF, which are critical for host resistance to many intracellular pathogens, are also detrimental when expressed in an uncontrolled manner (1). Murine infection with the protozoan parasite Toxoplasma gondii provides an excellent example of this concept. IL-12–dependent production of IFN-γ is essential for the control of both acute and chronic T. gondii infection (2). At the same time, IL-10–deficient mice, which display normal resistance to infection, succumb to excessive tissue damage associated with the overproduction of the proinflammatory cytokines listed above (3, 4). Similar scenarios in which dysregulated pathogen-induced cytokine production results in inflammatory disease have been observed in a wide variety of parasitic (5) and bacterial (6, 7) infections.

In addition to down-regulatory cytokines, other endogenous mediators may play an important role in controlling excess production of host-protective proinflammatory cytokines. In the process of studying the response of murine dendritic cells (DCs)* to T. gondii, we recently uncovered a novel mechanism for the regulation of IL–12 production involving lipoxin (LX)A₄, an eicosanoid product generated from arachidonic acid. Splenic DCs from mice injected with soluble tachyzoite antigen (STAg) of T. gondii produce high levels of IL–12 by a mechanism dependent on the cell-surface expression of the chemokine receptor CCR5 (8). However, this response is short-lived and cannot be restimulated with STAg for a period of ~1 wk (9). We found that the observed loss of responsiveness was associated with the induction of host LXs for the in vivo regulation of proinflammatory responses during microbial infection.

Address correspondence to Julio Aliberti, Immunobiology Section, Laboratory of Parasitic Diseases, NIAID/NIH, 50 South Drive, MSC 8003, Bethesda, MD 20892. Phone: 301-402-9489; Fax: 301-402-0890; E-mail: jaliberti@niaid.nih.gov

*Abbreviations used in this paper: 5-LO, 5-lipoxygenase; DC, dendritic cell; FPRL, formyl-peptide receptor-like receptor; LX, lipoxin; MIP, macrophage inflammatory protein; NO₂, nitrite; STAg, soluble tachyzoite antigen.
ciated with reduced expression of CCR5 by DCs, a phenomenon dependent on the presence of an enzyme, 5-lipoxygenase (5-LO), critical in the generation of LXA_{4}. Moreover, suppressed IL-12 production by DCs could be induced exogenously by the administration of a stable LXA_{4} mimic (10). Other eicosanoids generated by the 5-LO pathway including leukotrienes (LTB_{4}, LTC_{4}, and LTD_{4}) as well as 5-Oxo-ETE, 5-HETE, and a battery of related compounds were not able to mimic the activity of LXA_{4} when tested in the nanogram to microgram range. On the basis of the evidence above, we hypothesized that the induction of LXA_{4} by STAg is the mechanism responsible for the down-regulation of CCR5-dependent IL-12 production observed after the administration of this microbial stimulus.

Although LXA_{4} is able to potently suppress T. gondii–induced IL-12 production by DCs, our previous demonstration of this phenomenon involved a nonphysiological model system using STAg injection. A critical question remained as to whether the same mechanism functions in the regulation of IL-12 and IL-12–dependent IFN-γ synthesis during natural infection with T. gondii and whether it impacts on the outcome of disease. In this study, we have addressed this issue by investigating the induction of LXA_{4} after the infection of mice with an avirulent strain of T. gondii and after the fate of such infections in 5-LO–/– animals incapable of generating the eicosanoid. Our findings reveal a critical role for T. gondii–induced LXA_{4}, distinct from that of IL-10 in the regulation of IL-12–dependent IFN-γ production and tissue damage during infection with this protozoan. Thus, they demonstrate a previously unrecognized function for this lipid mediator in modulating the inflammatory response triggered in vivo by infectious agents.

Materials and Methods

Animals. Wild-type controls (B6, 129S F2/j) and 5-LO–deficient (B6, 129S Alox-5) mice were obtained from The Jackson Laboratory and bred and maintained in an NIAID Association for the Assessment and Accreditation of Laboratory Animal Care–accredited animal facility. Previous studies with the experimental model used indicated no major differences in the susceptibility to T. gondii of B6 and B6 × 129 crosses over the first 3 mo of infection (11). Animals 5–7-wk-old of both sexes were used on a randomized basis in all experiments.

Infectious and In Vivo Treatments. T. gondii cysts (ME49 strain) were recovered from brain homogenates from chronically infected mice and suspended in PBS. Animals were experimentally infected by intraperitoneal injection with 20 cysts per mouse. In some experiments, animals also received five intraperitoneal injections in alternating days with vehicle (0.2 ml/animal), IL-10 (0.1 μg/animal), and 15-cpi-16-phenoxo-parafluoro-LXA_{4}-methyl ester (1 μg/animal/treatment, 0.025 mg/kg; Berlex Biosciences) from days 10–20 after infection. The LX analogue was prepared by total organic synthesis and isolated and characterized as previously described (12).

LXA_{4}, Nitrite (NO_{2}−), and Cytokine Determinations. Serum levels of LXA_{4} were measured according to the procedure of Levy et al. (13) using a commercial kit (Neogen). NO_{2}− levels were evaluated in culture supernatants by means of the Griess reaction (3). IL-12p40, IFN-γ, and IL-10 serum levels were measured by ELISA as previously described (8, 14), whereas macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES were quantitated using commercial ELISA kits (R&D Systems).

In Situ Staining and Flow Cytometry. In situ immunostaining of CD4, CD8, CD11c, IL-12p40, and CCR5 was performed as previously described (8). In brief, acetone-fixed serial sections were incubated with biotin-conjugated antibodies against CD4, CD8, CD11c, or CCR5 (Becton Dickinson). After washing, sections were exposed to streptavidin–conjugated horseradish peroxidase (Jackson ImmunoResearch Laboratories) and the reaction was developed using a metal-conjugated horseradish peroxidase substrate (Pierce Chemical Co.). In some experiments, sections were simultaneously double stained with rat anti–IL-12p40 mAb and the reaction was developed with anti–rat IgG AlexaFluor 594 (Molecular Probes) followed by counterstaining with DAPI (Molecular Probes). After additional washing, the sections were examined microscopically and the images were recorded with a digital camera (×200). For flow cytometric analysis, brain mononuclear cell suspensions were prepared and stained with anti-CD11c, anti-CD11b, and anti-CCR5 (Becton Dickinson) as previously described (15).

Macrophage Cultures. Thioglycollate-elicited macrophages were obtained from C57BL/6 mice 5 d after injection. Cells were plated, incubated with different concentrations of LXA_{4}, IL-10, or vehicle for 1 h, and infected with T. gondii tachyzoites (5:1 parasite/macroage ratio). After 4 or 48 h the cultures were stopped, the cells were fixed, Wright-Giemsa stained, and the number of intracellular parasites were evaluated microscopically. In parallel cultures, 24-h supernatants were collected for later evaluation of NO_{2}−, cytokine, and chemokine levels.

Statistical Analysis. The statistical significance of differences in mean values between experimental versus control or vehicle treated samples was evaluated by means of Student’s t test. Differences were considered to be significant at P values of < 0.05.

Results

T. gondii Infection Induces LXA_{4} Production In Vivo. To address whether the regulatory effects of LXA_{4} on IL-12 production play a role in the outcome of in vivo infection with T. gondii, we first determined whether the mediator is induced after natural exposure to the live parasite. As shown in Fig. 1 A, LXA_{4} was detected at substantial levels in sera of wild-type mice after intraperitoneal inoculation with T. gondii cysts beginning at 10 d and reaching a plateau 15 d after infection. Importantly, only baseline levels of the eicosanoid were detected in simultaneously infected 5-LO–/– mice, confirming the dependence of LXA_{4} production on 5-LO in vivo. In contrast, serum IL-10 levels peaked earlier (5–10 d after infection) and were only marginally affected by 5-LO deficiency (Fig. 1 B). These observations demonstrate that IL-10 and LXA_{4} are induced with different kinetics, suggesting that they may involve distinct pathways.

5-LO–/– Mice Display Increased Susceptibility to T. gondii Infection. To assess whether the induction of LXA_{4} plays a role in host resistance, we compared the outcome of infection in wild-type and 5-LO–/– mice. As shown in Fig. 2, A
Figure 1. LXA4 and IL-10 are induced with different kinetics during T. gondii infection. Wild-type and 5-LO–deficient mice were infected intraperitoneally with 20 cysts of T. gondii (ME49 strain) and at the indicated times the animals were bled and LXA4 and IL-10 levels were assessed by ELISA in the serum. The values represent mean ± SD of triplicate samples of at least three animals per time point per group. The experiment shown is representative of two performed.

and B, ME49-inoculated 5-LO–deficient mice exhibited an accelerated loss in body weight and abruptly succumbed between 27 and 31 d after infection in contrast to the long-term survival of wild-type animals. Importantly, this increased susceptibility to T. gondii was not the result of defective immune control of the parasite. Thus, infected 5-LO−/− mice consistently showed a lower rather than higher burden of T. gondii tissue cysts in the brain than the wild-type controls (Fig. 2 C). This finding suggested that parasite–induced immune responses are enhanced in the absence of LXA4 generation.

T. gondii–infected Mice Show Augmented Proinflammatory Cytokine Production and Tissue Pathology in the Absence of 5-LO. To determine whether the absence of 5-LO affects parasite-induced proinflammatory cytokine responses, we studied the kinetics of serum IL-12, IFN-γ, and TNF production in T. gondii–infected animals. Consistent with the observation of lower parasite burdens, serum levels of IL-12 and IFN-γ were found to be significantly elevated in infected 5-LO−/− mice compared with their wild-type counterparts (Fig. 2 D and E). Particularly striking was the uncontrolled increase in IL-12 production observed with time in the knockout animals. Although serum TNF levels also appeared to be elevated in the 5-LO−/− mice, the observed increases were not statistically significant (Fig. 2 F).

The appearance of elevated proinflammatory cytokine production in the presence of decreased parasite numbers suggested that the increased mortality of 5-LO−/− mice results from cytokine–induced tissue damage. In support of this hypothesis, brain sections from the knockout animals 25 d after infection showed markedly enhanced meningitis when compared with equivalent sections from infected wild-type control mice (unpublished data). In addition, the 5-LO–deficient brain tissue displayed increased encephalitis with CD4+ and CD8+ cell infiltration (Fig. 3 A, d and e, and B). As expected from our recent findings demonstrating a suppressive influence of 5-LO on CCR5 expression (10), staining for this chemokine receptor was also enhanced in the same sections from infected knockout mice (Fig. 3 A, f and C and D). In contrast to the brain, no evidence of enhanced tissue damage was observed in the liver and spleen of the same infected 5-LO−/− animals (unpublished data).

When brain sections from the same infected wild-type (Fig. 4 a) and 5-LO−/− (Fig. 4 b) mice were stained for IL-12p40 (red), a massive increase in the intensity of expression and frequency of positive cells was observed in the latter samples. Some, but not all of this staining was associated with CD11c+ cells (green), suggesting that in this model 5-LO regulates IL-12 expression in both DCs as well as other cells in the tissue infiltrates.

In Vivo Administration of a Stable LXA4 Analogue Rescues 5-LO−/− Mice from T. gondii–induced Mortality. Although 5-LO−/− mice are clearly unable to produce LXA4 in response to T. gondii infection, it was still possible that the absence of a different 5-LO–dependent metabolic product accounts for the increased IL-12 production and mortality seen in the knockout animals. To attempt to confirm the role of LXA4 in the 5-LO–dependent suppression observed, we reconstituted T. gondii–infected 5-LO–deficient animals by injecting them every other day with a stable analogue of LXA4 (15-epi-16-phenoxy-parafluor-LXA4 methyl ester). To additionally examine possible redundancies in the activities of LXA4 and IL-10, a second group of infected 5-LO−/− mice was injected with IL-10 using the same regimen. As expected, nonreconstituted 5-LO−/− animals succumbed ~25–28 d after infection (Fig. 5 A). However, treatment with 0.25 mg/kg LX analogue rescued these animals from death increasing their survival time to >80 d (Fig. 5 A and unpublished data). In contrast, IL-10–treated 5-LO−/− mice succumbed much earlier, between 43 and 50 d after infection. Interestingly, when brain cysts were enumerated on day 25, an increased frequency (P < 0.05) was observed in the IL-10–treated wild-type and 5-LO−/− animal groups when compared with those assayed in untreated control groups (Fig. 5 B). In contrast, LX analogue treatment caused a smaller but significant elevation in the cyst counts in the brains of 5-LO−/− mice but did not affect cyst numbers in wild-type animals.
Nevertheless, LX treatment restored parasite burdens in the 5-LO−/− tissues to the levels observed in the 5-LO–sufficient controls (Fig. 5 B).

To additionally analyze the effects of LX and IL-10 reconstitution, we evaluated serum levels of IL-12, IL-10, and IFN-γ 20 d after infection, a time point at which IL-12 production in wild-type animals has stabilized but remains elevated with respect to uninfected mice. As previously described (Fig. 2), nonreconstituted infected 5-LO−/− mice displayed significantly higher levels of IL-12 and IFN-γ than these infected control animals. Importantly, LX treatment significantly lowered the concentrations of both cytokines and in the case of IFN-γ, restored its concentration to the level observed in wild-type controls (Fig. 5, C and D). In contrast, LX analogue administration had no detectable effect on IL-10 levels (Fig. 5 E), arguing that the activity of the compound is not due to the stimulation of IL-10 production. On the other hand, IL-10 treatment of both wild-type and knockout animals caused decreases in both IL-12 and IFN-γ as well as an increase in endogenous IL-10 (Fig. 5, C–E). Neither IL-10 or LX analogue treatment resulted in significant changes in LXA4 levels in sera of either wild-type or 5-LO–deficient animals (unpublished data). The above experiments argue that the increased susceptibility of 5-LO−/− mice to T. gondii is the result of the loss of LX production and that LX and IL-10 regulate cytokine production and host mortality by different mechanisms.

**Figure 2.** 5-LO−/− mice infected with T. gondii display profound weight loss and accelerated mortality despite the presence of lower parasite burdens and elevated proinflammatory cytokine production. Wild-type (B6, 129J F2) and 5-LO–deficient (B6, 129J Alox-5) animals (males and females) were infected as described in Fig. 1 and (A) body weight and (B) survival rates were monitored during the times indicated (n = 15 animals per group, per experiment). (C) To evaluate parasite load, the animals were killed and cysts were counted in brain homogenates. For systemic cytokine production, mice were bled at the indicated time points and the levels of (D) IL-12p40, (E) IFN-γ, and (F) TNF were measured in serum by ELISA. The values presented are the mean ± SD of at least three animals per time point per group. The experiments shown are representative of at least two performed that gave similar results. *, statistically significant (P < 0.05) differences between the means of the values obtained with 5-LO-deficient versus wild-type control mice.
two mediators in a variety of assays of microbicidal and proinflammatory response. To measure their effects on lymphokine-mediated intracellular control of parasite growth, we preincubated elicited peritoneal macrophages with LXA₄ or IL-10 and then infected the cells with tachyzoites of *T. gondii* in the presence of IFN-γ. After 48 h, the macrophages were Giemsa stained and the number of intracellular parasites was evaluated by microscopy. As shown in Fig. 6 A, IL-10, but not LXA₄ suppressed the microbiostatic effects of IFN-γ on intracellular *T. gondii* growth. Consistent with this observation, IL-10, but not LXA₄ inhibited nitric oxide production by the same cells (Fig. 6 B). In contrast, both IL-10 and LXA₄ pretreatment suppressed TNF (Fig. 6 C), MIP-1β, and RANTES (unpublished data) production whereas IL-10 slightly enhanced and LXA₄ markedly inhibited MIP-1α secretion (Fig. 6 D) in these cultures. Thus, although LXA₄ lacks the suppressive effects on macrophage effector function dis-
played by IL-10, it shares with IL-10 the ability to inhibit the proinflammatory cytokine and chemokine responses generated by these cells upon lymphokine activation.

Discussion

IL-12 plays a fundamental role in the induction of both innate and adaptive resistance to intracellular pathogens and as a product of APC is a primary mediator of immune function. Because of its potential toxicity when produced in excess, IL-12 production is known to be carefully regulated by a remarkably large number of different mechanisms (16). The major mediators previously implicated in the control of pathogen-induced IL-12 synthesis are the down-regulatory cytokines IL-10 and TGF-β. The results presented here reveal a new in vivo pathway for the regulation of IL-12–dependent antimicrobial immune responses involving the eicosanoid LXA₄.

LXA₄ was originally described as a selective regulator of leukotriene function (17) biosynthesized by leukocytes, endothelial cells, and platelets by means of transcellular pathway(s) (18). In later studies, LXA₄ was shown to have potent inhibitory effects on several inflammatory mechanisms, including NK cell cytotoxicity (19), leukocyte responses to cytokines (e.g., TNF; reference 20), or to microbial stimulation (21), neutrophil and eosinophil migration (22, 23), as well as cell surface expression of P selectin and LFA-1 (24, 25).

The possibility that LXA₄ centrally regulates immune responses was suggested by our recent findings indicating that the eicosanoid suppresses STAg-induced production of IL-12 by DCs both in vitro and in vivo (10). Although the
molecular mechanism for this inhibition was not elucidated;
we proposed that it involves the down-regulation of CCR5 expression as a consequence of interaction of LXA₄ with the formyl-peptide receptor-like receptor (FPRL) 1, a phenomenon previously described when FPRL-1 on human monocytes interacts with a peptide from HIV Gp120 (26). Although it is not yet clear whether FPRL-1 is the receptor responsible for these biological effects of LXA₄, a recent study in which the transfection of HeLa cells with FPRL-1 led to LXA₄ responsiveness as assessed by the inhibition of nuclear factor κB activation (27) supports the existence of this pathway. Regardless of the precise mechanism involved, it is clear from both the latter study and our own previous observations that exogenous LXA₄ can have profound global effects on the immune response to microbial stimulation inhibiting DC migration and function as well as the induction of proinflammatory gene expression (10, 27).

Although our previous experiments also suggested that STAg itself induces LXA₄-mediated inhibition of DC function in vivo, they did not address the physiological relevance of this response during natural infection. This study establishes that LXA₄ is induced by T. gondii in vivo and this response plays a major host protective role in preventing parasite-induced inflammation and mortality. Upon infection with the protozoan, 5-LO⁻/⁻ mice succumbed during the early chronic phase but displayed a significantly reduced parasite load. Instead, mortality ap-

Figure 5. In vivo administration of a stable analogue of LXA₄ rescues 5-LO⁻/⁻ animals from mortality induced by T. gondii infection. Wildtype controls or 5-LO⁻/⁻ mice were infected with T. gondii as described above and treated every other day from days 10 to 20 with vehicle (0.2 ml/animal/time), LXA₄ analogue (1 µg/animal/time), or IL-10 (0.1 µg/animal/time). (A) Survival rates, (B) cysts counts, (C) serum IL-12, and (D) serum IFN-γ levels were assessed as previously described. Values presented are the mean ± SD of triplicate samples of five animals per group. *, statistically significant (P < 0.05) differences between group means.
Redundant and nonredundant roles of IL-10 and LXA₄ in regulating IL-12–dependent IFN-γ production during T. gondii infection. The observations that IL-10–deficient mice succumb 10–14 d after infection whereas 5-LO⁻/⁻ mice survive for an additional 10–15 d suggests that these two down-regulatory mediators may have distinct functions but work in synergy to protect the host against excess proinflammatory cytokine production. Consistent with this hypothesis is our observation that the reconstitution of 5-LO⁻/⁻ mice with LXA₄ analogue early in infection resulted in complete protection against parasite-induced mortality and restored both IL-12 and IFN-γ to levels comparable to those in infected wild-type animals. Although this observation does not rule out the possible participation of other 5-LO dependent eicosanoids, it argues strongly that LXA₄ is sufficient to mediate the protection against cytokine-associated mortality revealed by the behavior of T. gondii–exposed 5-LO–deficient animals.

A major question raised by our findings concerns the relative roles of IL-10 and LXA₄ in regulating IL-12–dependent IFN-γ production during T. gondii infection. The observations that IL-10–deficient mice succumb 10–14 d after infection whereas 5-LO⁻/⁻ mice survive for an additional 10–15 d suggests that these two down-regulatory mediators may have distinct functions but work in synergy to protect the host against excess proinflammatory cytokine production. Consistent with this hypothesis is our observation that the reconstitution of 5-LO⁻/⁻ mice with LXA₄ at a time when endogenous IL-10 levels have waned protects the animals for a short period of only 15–20 d, in contrast to the long-lasting protection induced by LXA₄ reconstitution. These findings suggest that although IL-10 is sufficient to down-regulate IL-12 and other proinflammatory cytokines during initial acute infection, LXA₄ is necessary to sustain long-term stabilization of these responses during chronic infection. Because it is now clear that the continued IL-12 production is required for the maintenance of host resistance to the parasite (14), it is possible that LXA₄ may provide a mechanism for fine-tuning this response not afforded by IL-10 alone. In this regard, our observation that LXA₄ lacks the suppressive activities on macrophage effector functions displayed by IL-10 (Fig. 5) supports the concept that its key role in T. gondii infection may be to regulate IL-12–dependent IFN-γ responses.
Although the results of this study point to a major role for endogenous LXA₄ in the regulation of IL-12 responsiveness to T. gondii infection, it is important to note that the IL-12 response to this parasite is unusual in its dependence on CCR5 signaling. Thus, it is presently unclear whether this LX may exert the same regulatory effects on proinflammatory cytokine production induced by other pathogens. Nevertheless, the observation that exogenous LXA₄ dramatically inhibits proinflammatory cytokine gene expression in murine epithelial cells exposed to Salmonella typhimurium (27) as well as our own observation that LXA₄-treated mice show highly defective DC migration in response to LPS as well as STAg (10) argues that if induced after infection, LX may trigger endogenous LXA₄ production. The identification of the specific microbial products that stimulate LXA₄ biosynthesis and the signaling pathway(s) involved should yield information important for our understanding of the immunoregulation of the response to pathogens as well as the development of new strategies for manipulating the induction of this potent antiinflammatory mediator.

We thank Dr. Allen Cheever for histopathologic analysis and Dr. David Sacks and James Jolundrow for helpful discussions.

This work was supported in part by NIH grants GM 38765 and PO1-DE 13499 to C. Serhan.

Submitted: 12 July 2002
Revised: 5 September 2002
Accepted: 1 October 2002

References


